Advanced Search

Preplanned Studies: Genomic Insights into Genetic Characteristics of Chromobacterium haemolyticum — China, 2023

View author affiliations
  • Summary

    What is already known about this topic?

    Chromobacterium haemolyticum (C. haemolyticum) is an emerging multidrug-resistant and potentially extensively drug-resistant pathogen capable of causing invasive, lethal infections in humans. Conventional biochemical and mass spectrometry identification methods used in clinical laboratories cannot reliably distinguish it from C. violaceum.

    What is added by this report?

    This study provides the first report characterizing the genomic features of C. haemolyticum isolated from a young patient in China and reveals the evolutionary patterns of global C. haemolyticum isolates.

    What are the implications for public health practice?

    This research highlights the advantages of whole-genome sequencing for accurate differentiation of Chromobacterium species, raises public awareness about this uncommon pathogen, and provides scientific foundations for improved detection and prevention strategies.

  • loading...
  • Conflicts of interest: No conflicts of interest.
  • Funding: Supported by grants from the National Key Research and Development Program of China (2023YFC2307101), the Young TopNotch Talents Foundation of Henan Agricultural University (30501278), and Project for Young Scientist of the Joint Funds of Science and Technology Research and Development Plan of Henan Province, China (235200810058)
  • [1] DSMZ-Deutsche sammlung von mikroorganismen und zellkulturen. 2024. https://www.bionity.com/de/lexikon/Deutsche_Sammlung_von_Mikroorganismen_und_Zellkulturen.html.
    [2] Alisjahbana B, Debora J, Susandi E, Darmawan G. Chromobacterium violaceum: a review of an unexpected scourge. Int J Gen Med 2021;14:3259 − 70. https://doi.org/10.2147/IJGM.S272193.
    [3] Han XY, Han FS, Segal J. Chromobacterium haemolyticum sp. nov., a strongly haemolytic species. Int J Syst Evol Microbiol 2008;58(Pt 6):1398-403. http://dx.doi.org/10.1099/ijs.0.64681-0.
    [4] Iwamoto K, Yamamoto M, Yamamoto A, Sai T, Mukai T, Miura N, et al. Meningitis caused by Chromobacterium haemolyticum suspected to be derived from a canal in Japan: a case report. J Med Case Rep 2023;17(1):171. https://doi.org/10.1186/s13256-023-03913-1.
    [5] CLSI. CLSI M100 Performance standards for antimicrobial susceptibility testing. 33rd ed. CLSI, 2023. https://clsi.org/about/news/clsi-publishes-m100-performance-standards-for-antimicrobial-susceptibility-testing-33rd-edition/.
    [6] Teixeira P, Tacão M, Baraúna RA, Silva A, Henriques I. Genomic analysis of Chromobacterium haemolyticum: insights into the species resistome, virulence determinants and genome plasticity. Mol Genet Genomics 2020;295(4):1001 − 12. https://doi.org/10.1007/s00438-020-01676-8.
    [7] Blanco-Míguez A, Beghini F, Cumbo F, Mciver LJ, Thompson KN, Zolfo M, et al. Extending and improving metagenomic taxonomic profiling with uncharacterized species using MetaPhlAn 4. Nat Biotech 2023;41(11):1633 − 44. https://doi.org/10.1038/s41587-023-01688-w.
    [8] Pei YH, Wei B, Huang HR, Wang YN, Xu XB. Global population structure and genomic insights into Chromobacterium violaceum of human invasive lethal infection and non-human origins. J Infect 2024;89(6):106332. https://doi.org/10.1016/j.jinf.2024.106332.
    [9] Wang YN, Liu Y, Lyu N, Li ZY, Ma SF, Cao DM, et al. The temporal dynamics of antimicrobial-resistant Salmonella enterica and predominant serovars in China. Natl Sci Rev 2023;10(3):nwac269. https://doi.org/10.1093/nsr/nwac269.
    [10] Wang YN, Xu XB, Jia SL, Qu MQ, Pei YH, Qiu SF, et al. A global atlas and drivers of antimicrobial resistance in Salmonella during 1900-2023. Nat Commun 2025;16(1):4611. https://doi.org/10.1038/s41467-025-59758-3.
    [11] Wang YN, Xu XB, Zhu BL, Lyu N, Liu Y, Ma SF, et al. Genomic analysis of almost 8,000 Salmonella genomes reveals drivers and landscape of antimicrobial resistance in China. Microbiol Spectr 2023;11(6):e0208023. https://doi.org/10.1128/spectrum.02080-23.
    [12] Lv PP, Pei YH, Jiang Y, Wang Q, Liu Y, Qu MQ, et al. Genomic insights into antibiotic-resistant non-typhoidal Salmonella isolates from outpatients in Minhang District in Shanghai. Commun Med 2025;5(1):228. https://doi.org/10.1038/s43856-025-00950-3.
    [13] World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance. Geneva: World Health Organization; 2024. https://www.who.int/publications/i/item/9789240093461.
    [14] Ma YY, Chen P, Mo Y, Xiao YH. WHO revised bacterial priority pathogens list to encourage global actions to combat AMR. hLife 2024;2(12):607 − 10. https://doi.org/10.1016/j.hlife.2024.10.003.
    [15] Xiao YH, Nishijima T. Status and challenges of global antimicrobial resistance control: a dialogue between Professors Yonghong Xiao and Takeshi Nishijima. hLife 2024;2(2):47 − 9. https://doi.org/10.1016/j.hlife.2023.11.004.
    [16] Gudeta DD, Bortolaia V, Jayol A, Poirel L, Nordmann P, Guardabassi L. Chromobacterium spp. harbour Ambler class A β-lactamases showing high identity with KPC. J Antimicrob Chemother 2016;71(6):1493 − 6. https://doi.org/10.1093/jac/dkw020.
  • FIGURE 1.  Phylogenetic analysis of 19 C. haemolyticum genomes.

    Note: Phylogenetic tree-built details and analysis are described in the text. Collection date, country, source, continent, and outcome are labeled with different colors. The red and blue triangles represent the existence of VFs and ARGs, respectively.

    Abbreviation: VFs=virulence factors; ARGs=antibiotic resistance genes.

    TABLE 1.  Results of antibiotic susceptibility testing.

    Antibiotic MIC (µg/mL) Interpretation
    Imipenem 4 S
    Meropenem ≤1 S
    Piperacillin ≥128 R
    Piperacillin/tazobactam ≤4/4 S
    Cefepime ≤2 S
    Ceftazidime ≤2 S
    Minocycline ≤4 S
    Cefoperazone/Sulbactam ≤8/4 S
    Sulfamethoxazole/Trimethoprim ≤1/19 S
    Gentamicin ≤2 S
    Amikacin 32 I
    Levofloxacin ≤1 S
    Ciprofloxacin ≤0.5 S
    Chloramphenicol ≤8 S
    Aztreonam ≤2 S
    Note: S indicates sensitivity, R indicates resistant, and I indicates intermediate.
    Download: CSV

Citation:

通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索
Turn off MathJax
Article Contents

Article Metrics

Article views(530) PDF downloads(1) Cited by()

Share

Related

Genomic Insights into Genetic Characteristics of Chromobacterium haemolyticum — China, 2023

View author affiliations

Summary

What is already known about this topic?

Chromobacterium haemolyticum (C. haemolyticum) is an emerging multidrug-resistant and potentially extensively drug-resistant pathogen capable of causing invasive, lethal infections in humans. Conventional biochemical and mass spectrometry identification methods used in clinical laboratories cannot reliably distinguish it from C. violaceum.

What is added by this report?

This study provides the first report characterizing the genomic features of C. haemolyticum isolated from a young patient in China and reveals the evolutionary patterns of global C. haemolyticum isolates.

What are the implications for public health practice?

This research highlights the advantages of whole-genome sequencing for accurate differentiation of Chromobacterium species, raises public awareness about this uncommon pathogen, and provides scientific foundations for improved detection and prevention strategies.

  • 1. Department of Laboratory Medicine, Qintang District People’s Hospital, Guigang City, Guangxi Zhuang Autonomous Region, China
  • 2. International Joint Research Center of National Animal Immunology, College of Veterinary Medicine, Henan Agricultural University, Zhengzhou City, Henan Province, China
  • 3. CAS Key Laboratory of Pathogen Microbiology and Immunology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, China
  • 4. Longhu Laboratory of Advanced Immunology, Zhengzhou City, Henan Province, China
  • 5. Henan Academy of Innovations in Medical Science, Zhengzhou City, Henan Province, China
  • 6. Division of Pathogen Testing and Analysis, Shanghai Municipal Center for Disease Control and Prevention, Shanghai, China
  • Corresponding authors:

    Xuebin Xu, xuxuebin@scdc.sh.cn

    Yanan Wang, wangyanan1001@henau.edu.cn

  • Funding: Supported by grants from the National Key Research and Development Program of China (2023YFC2307101), the Young TopNotch Talents Foundation of Henan Agricultural University (30501278), and Project for Young Scientist of the Joint Funds of Science and Technology Research and Development Plan of Henan Province, China (235200810058)
  • Online Date: August 08 2025
    Issue Date: August 08 2025
    doi: 10.46234/ccdcw2025.148
    • Introduction: Chromobacterium haemolyticum (C. haemolyticum) can cause invasive infections in humans. This study aims to reveal the genomic characteristics of C. haemolyticum and provide guidance for clinical diagnosis, treatment, prevention, and control.

      Methods: Species identification was performed through isolation culture and matrix-assisted laser desorption ionization time-of-flight mass spectrometry. Antibiotic susceptibility testing determined resistance phenotypes. High-throughput sequencing and bioinformatics methods were used to predict antibiotic resistance genes and virulence genes and to analyze the evolutionary characteristics of global C. hemolyticus genomes.

      Results: In this study, a C. haemolyticum strain was isolated from the bronchoalveolar lavage fluid of a patient in Guangxi Zhuang Autonomous Region, China. The isolate was sensitive to chloramphenicol, macrolides, and trimethoprim, while resistant to beta-lactams. Comparative genomics analysis revealed that most global strains carry carbapenemase-encoding genes. Phylogenetic analysis showed that the strain from this patient was closely related to a pond-derived C. haemolyticum isolate from Yangzhou, China.

      Conclusions: This study uncovered the genetic characteristics of C. haemolyticum from various sources worldwide, including antibiotic resistance and virulence factors, providing an important reference for clinical treatment.

    • The genus Chromobacterium belongs to the family Neisseriaceae and comprises 19 species (1). Chromobacterium violaceum (C. violaceum) is a zoonotic pathogen found in tropical and subtropical regions that can cause severe sepsis with high mortality rates in humans (2). Since the first report of C. haemolyticum in 2008 (3), most invasive infection cases (e.g., pneumonia and bacteremia) have been associated with exposure to water bodies (4). However, genomic data on C. haemolyticum remains insufficient worldwide.

      Here, we report the first case of pulmonary infection caused by Chromobacterium spp. in Guigang City, Guangxi Zhuang Autonomous Region, China. On the evening of November 4, 2023, an 18-year-old patient was admitted to the Qintang District People’s Hospital following a traffic accident in Guigang City. The patient subsequently developed pneumonia and a Chromobacterium spp. strain was isolated from bronchoalveolar lavage fluid. After combined treatment with cefoperazone sodium/sulbactam sodium, meropenem, and levofloxacin, the patient recovered.

      Antibiotic susceptibility testing (AST) was conducted according to the Clinical and Laboratory Standards Institute (CLSI) guidelines for non-Enterobacteriaceae bacteria to determine the minimum inhibitory concentration (MIC) of the C. haemolyticum strain (5). The AST results are presented in Table 1. Overall, the strain demonstrated sensitivity to most antibiotics tested while exhibiting resistance to several beta-lactam and aminoglycoside antibiotics (Table 1 and Supplementary Table S1).

      Antibiotic MIC (µg/mL) Interpretation
      Imipenem 4 S
      Meropenem ≤1 S
      Piperacillin ≥128 R
      Piperacillin/tazobactam ≤4/4 S
      Cefepime ≤2 S
      Ceftazidime ≤2 S
      Minocycline ≤4 S
      Cefoperazone/Sulbactam ≤8/4 S
      Sulfamethoxazole/Trimethoprim ≤1/19 S
      Gentamicin ≤2 S
      Amikacin 32 I
      Levofloxacin ≤1 S
      Ciprofloxacin ≤0.5 S
      Chloramphenicol ≤8 S
      Aztreonam ≤2 S
      Note: S indicates sensitivity, R indicates resistant, and I indicates intermediate.

      Table 1.  Results of antibiotic susceptibility testing.

      The isolate was initially identified as C. violaceum using blood agar culture, biochemical experiments, and matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS) (model: VITEK MS, version: VITEK MS V3.0, BioMérieux, France). Due to similar cultural characteristics between the two species, C. haemolyticum is frequently misidentified as C. violaceum (6). Definitive identification as C. haemolyticum was subsequently achieved (Supplementary Table S2) using MetaphlAn4 with database version mpa_vOct22_CHOCOPhlAnSGB_202212 (7).

      We downloaded 19 publicly available genomes of C. haemolyticum from the National Center for Biotechnology Information (NCBI) to characterize genomic features. After excluding two low-quality genomes (GCF_000285415.1 and GCF_003332145.1), the remaining 17 genomic datasets were used for subsequent analysis (Supplementary Table S3). We detected 12 antibiotic resistance genes (ARGs) classified into 7 categories (Supplementary Tables S1 and Supplementary Table S4). The predominant ARGs were rpsJ and four mutated genes: gidB, MurA, folP, and gyrA. Additionally, carbapenemase-encoding genes, including blaCRH-1, blaCRH-2, and blaCRH-3 were detected in 72.22% (13/18), 11.11% (2/18), and 16.67% (3/18) isolates, respectively. Moreover, we identified five types of multiple efflux pump systems-encoding genes (EmrAB-OMF, EmrAB-TolC, MdfA/CMr, MdtABC-TolC, and MacAB-TolC) that can reduce drug susceptibility.

      We detected 9 virulence factors (VFs), with 33.33% (3/9) belonging to the type 3 secretion system (Supplementary Table S5). Among these VFs, sicA, spaQ, spaT, fba, hfq, and recA were present in all strains. To investigate potential drivers mediating ARGs and VFs transfer, we identified 59 intact prophages belonging to 19 types (Supplementary Table S6). The most prevalent prophage was Mannhe_vB_MhM_3927AP2 (83.33%), followed by Ralsto_RSA1 (33.33%), Haemop_SuMu (27.78%), and Burkho_phiE125 (27.78%).

      To explore the population evolution of C. haemolyticum, we analyzed 18 public C. haemolyticum genomes and 2 C. violaceum genomes (8). The phylogenetic tree revealed two distinct lineages corresponding to the two different species, spanning five countries and four diverse sources (human, water, environment, and Aedes aegypti) (Figure 1). Lineage one (L1) consisted of 2 C. violaceum strains from China, while lineage two (L2) comprised global C. haemolyticum strains. The isolate from the patient in this study showed a close genetic relationship with a pond-source C. haemolyticum strain from Yangzhou, China. Both isolates exhibited fewer virulence factors, with 6 VFs each.

      Figure 1. 

      Phylogenetic analysis of 19 C. haemolyticum genomes.

      Note: Phylogenetic tree-built details and analysis are described in the text. Collection date, country, source, continent, and outcome are labeled with different colors. The red and blue triangles represent the existence of VFs and ARGs, respectively.

      Abbreviation: VFs=virulence factors; ARGs=antibiotic resistance genes.

    • Advances in whole-genome sequencing (WGS) enable rapid and accurate species identification and tracking of potential factors and evolutionary patterns of existing and emerging antibiotic resistance (AMR) and virulence factors in bacteria that inhabit organisms and the environment (812) Using WGS, we successfully distinguished the genetic differences between the C. haemolyticum strain in our study and C. violaceum, confirming the identify of our isolate as C. haemolyticum (Supplementary Table S6).

      Carbapenem-resistant gram-negative bacteria pose a significant health burden (1315). Carbapenemase-encoding genes naturally exist in the chromosomes of Chromobacterium species (16). We detected blaCRH-1 in 13 strains of C. haemolyticum, while blaCRH-2 and blaCRH-3 were detected in 2 and 3 strains, respectively. Additionally, we identified mutated fluoroquinolone resistance genes (gyrA and gyrB) and the tetracycline resistance gene rpsJ. However, the C. haemolyticum isolate from our patient remained sensitive to ciprofloxacin, nalidixic acid, meropenem, tetracycline, and tigecycline, suggesting these ARGs may not be expressed (12).

      In summary, this is the first report characterizing the genome of C. haemolyticum causing human pulmonary infection in China. We found that the strain isolated from the recovered patient carried fewer virulence factors and shared a close genetic relationship with a water isolate from Yangzhou, China. Due to the limited number of available genomes, which may underestimate the global transmission risk of carbapenem-resistant C. haemolyticum, increased genomic surveillance is needed to better understand its spread and evolutionary trajectory. Our findings enhance awareness of this uncommon species and provide a scientific basis for the prevention and treatment of infections caused by C. haemolyticum in humans, food animals, and ornamental animals in the future.

    • The Veterinary Big Data and Bioinformatics Center, Henan Agricultural University for their support and assistance.

  • Conflicts of interest: No conflicts of interest.
  • Reference (16)

    Citation:

    Catalog

      /

      DownLoad:  Full-Size Img  PowerPoint
      Return
      Return